Matthew Galsky, MD

Matthew Galsky, MD, Icahn School of Medicine at Mount Sinai

Articles by Matthew Galsky, MD

Petros Grivas, MD, PhDAdvanced Urothelial Carcinoma | March 13, 2025
The panel elaborates on what excites them most about the future of UC research, highlighting promising advancements.
View More
Petros Grivas, MD, PhDAdvanced Urothelial Carcinoma | March 13, 2025
The panel considers the evolving role of ctDNA in guiding adjuvant therapy decisions, highlighting IMvigor011 and MODERN.
Petros Grivas, MD, PhDAdvanced Urothelial Carcinoma | March 13, 2025
The panel shares the NIAGARA findings and results from RETAIN-2 on dose-dense MVAC for bladder preservation.
Petros Grivas, MD, PhDAdvanced Urothelial Carcinoma | March 13, 2025
The panel covers 2L treatment options for mUC post-EV/pembro, with emphasis on platinum-based chemo and targeted therapy.
Petros Grivas, MD, PhDAdvanced Urothelial Carcinoma | March 13, 2025
The panel debates patient selection, alternative regimens, and the balance between escalation and de-escalation strategies.
Petros Grivas, MD, PhDAdvanced Urothelial Carcinoma | March 13, 2025
The panel weighs the impact of long-term survival data from the EV-302 trial, with significant improvements in OS.
Matthew Galsky, MDMuscle Invasive Urothelial Carcinoma | February 14, 2025
Dr. Galsky highlights the latest findings on the impact of pCR on long-term outcomes in the NIAGARA trial.
Matthew Galsky, MDMuscle Invasive Urothelial Carcinoma | February 20, 2025
Dr. Galsky provides comment on the additional efficacy outcomes in patients with MIBC from the CheckMate 274 study.
Matthew Galsky, MDAdvanced Urothelial Carcinoma | September 18, 2024
Dr. Galsky discusses the value of HER2 status and the promising 75% ORR from the phase 2 trial.
Matthew Galsky, MDAdvanced Urothelial Carcinoma | June 6, 2024
Drs. Galsky and Nizam spotlight a phase 3 study of disitamab vedotin for la/mUC that expresses HER2.
Matthew Galsky, MDAdvanced Urothelial Carcinoma | June 6, 2024
Drs. Matthew Galsky and Amanda Nizam break down the latest data subanalysis from the CheckMate 901 trial.
Matthew Galsky, MDMuscle Invasive Urothelial Carcinoma | May 20, 2024
Dr. Galsky shares the first OS data update on the CheckMate 274 trial, which he gave at the 2024 EAU Congress.
Peter O'Donnell, MDRoundtable | November 17, 2023
The panel shares their hopes for the future of bladder cancer treatment.
Peter O'Donnell, MDRoundtable | November 17, 2023
The panel shares tips for community oncologists who may not be familiar with treating patients with EV/pembro.
Peter O'Donnell, MDRoundtable | November 17, 2023
The panel shares treatment sequencing decisions based on a few patient scenarios.
Peter O'Donnell, MDRoundtable | November 17, 2023
The panel discussed the double antibody-drug conjugate trial that assessed sacituzumab govitecan plus EV.
Peter O'Donnell, MDRoundtable | November 17, 2023
The panel shares lessons learned from the phase THOR study.
Peter O'Donnell, MDRoundtable | November 17, 2023
The panel discusses the CheckMate 901 study results.
Peter O'Donnell, MDRoundtable | November 17, 2023
The panel discussed how the EV-302 data compare to the previous JAVELIN paradigm.
Peter O'Donnell, MDRoundtable | November 17, 2023
The panel discusses the "buzz" around the EV-302 study.